Class information for:
Level 1: FLUDARABINE//CHRONIC LYMPHOCYTIC LEUKEMIA//CLADRIBINE

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
3441 1907 39.7 80%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1265 8379 CHRONIC LYMPHOCYTIC LEUKEMIA//HAIRY CELL LEUKEMIA//CLL

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 FLUDARABINE Author keyword 128 35% 16% 300
2 CHRONIC LYMPHOCYTIC LEUKEMIA Author keyword 69 17% 19% 358
3 CLADRIBINE Author keyword 57 36% 7% 129
4 CLL Author keyword 41 19% 10% 198
5 2 CHLORODEOXYADENOSINE Author keyword 39 42% 4% 71
6 ALEMTUZUMAB Author keyword 33 22% 7% 130
7 2 CDA Author keyword 20 43% 2% 36
8 FLUDARABINE REFRACTORY Author keyword 18 89% 0% 8
9 CHRONIC LYMPHOCYTIC LEUKAEMIA Author keyword 16 16% 5% 94
10 REFRACTORY CLL Author keyword 15 88% 0% 7

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 FLUDARABINE 128 35% 16% 300 Search FLUDARABINE Search FLUDARABINE
2 CHRONIC LYMPHOCYTIC LEUKEMIA 69 17% 19% 358 Search CHRONIC+LYMPHOCYTIC+LEUKEMIA Search CHRONIC+LYMPHOCYTIC+LEUKEMIA
3 CLADRIBINE 57 36% 7% 129 Search CLADRIBINE Search CLADRIBINE
4 CLL 41 19% 10% 198 Search CLL Search CLL
5 2 CHLORODEOXYADENOSINE 39 42% 4% 71 Search 2+CHLORODEOXYADENOSINE Search 2+CHLORODEOXYADENOSINE
6 ALEMTUZUMAB 33 22% 7% 130 Search ALEMTUZUMAB Search ALEMTUZUMAB
7 2 CDA 20 43% 2% 36 Search 2+CDA Search 2+CDA
8 FLUDARABINE REFRACTORY 18 89% 0% 8 Search FLUDARABINE+REFRACTORY Search FLUDARABINE+REFRACTORY
9 CHRONIC LYMPHOCYTIC LEUKAEMIA 16 16% 5% 94 Search CHRONIC+LYMPHOCYTIC+LEUKAEMIA Search CHRONIC+LYMPHOCYTIC+LEUKAEMIA
10 REFRACTORY CLL 15 88% 0% 7 Search REFRACTORY+CLL Search REFRACTORY+CLL

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 FLUDARABINE PLUS CYCLOPHOSPHAMIDE 162 66% 8% 149
2 FLUDARABINE 123 27% 20% 387
3 STUDY GROUP GCLLSG 72 91% 2% 30
4 2 CHLORO 2 DEOXYADENOSINE 67 59% 4% 75
5 SUBCUTANEOUS ALEMTUZUMAB 44 81% 1% 26
6 2 CHLORODEOXYADENOSINE 40 26% 7% 132
7 2 CHLORODEOXYADENOSINE CLADRIBINE 38 89% 1% 17
8 INITIAL THERAPY 37 27% 6% 120
9 CHLORAMBUCIL 37 24% 7% 135
10 CONTINUOUS INFUSION SCHEDULE 34 93% 1% 13

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial 2015 3 23 61%
A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia 2015 2 25 76%
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus 2007 174 37 68%
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies 2013 29 79 54%
Infections in patients with chronic lymphocytic leukemia treated with fludarabine 1998 162 31 94%
State of the art treatment of chronic lymphocytic leukaemia 2011 27 67 91%
Update on Therapy of Chronic Lymphocytic Leukemia 2011 45 59 58%
Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia 2004 53 15 93%
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future 2015 3 49 27%
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia 2009 37 40 85%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 EXCELLENCE CELLULAR ST S PONSES AGING AS 10 73% 0.4% 8
2 GERMAN CLL STUDY GRP 6 80% 0.2% 4
3 ARTHUR JAMES COMPREHENS CANC 5 63% 0.3% 5
4 INTEGRATED ONCOL KOLN BONN 5 25% 0.8% 16
5 COPERNICUS MEM HOSP 3 16% 0.8% 16
6 TUMORAL METAB UNIT 3 60% 0.2% 3
7 IDA M CECIL H GREEN CANC 2 29% 0.3% 5
8 HEMATOL ONCOL IMMUNOL PALLIAT CARE INFECT DI 2 43% 0.2% 3
9 MOL TARGETS EXPT THER EUT 2 43% 0.2% 3
10 INTEGRATED ONCOL COLOGNE BONN 1 15% 0.5% 9

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000261644 BENDAMUSTINE//TREANDA//BENDAMUSTIN
2 0.0000248937 CLOFARABINE//CANC THER EUT IMMUNOL//NELARABINE
3 0.0000233135 CHRONIC LYMPHOCYTIC LEUKEMIA//CLL//B CLL
4 0.0000184221 CD20//OFATUMUMAB//OBINUTUZUMAB
5 0.0000106426 T CELL PROLYMPHOCYTIC LEUKEMIA//T PLL//TCL1
6 0.0000102225 HAIRY CELL LEUKEMIA//HAIRY CELL LEUKAEMIA//HAIRY CELL LEUKEMIA VARIANT
7 0.0000097837 RICHTERS SYNDROME//RICHTER SYNDROME//COMPOSITE LYMPHOMA
8 0.0000069073 WALDENSTROMS MACROGLOBULINEMIA//WALDENSTROM MACROGLOBULINEMIA//BING WALDENSTROMS MACROGLOBULINEMIA
9 0.0000062443 FOLLICULAR LYMPHOMA//NON HODGKINS LYMPHOMA//AGGRESSIVE NON HODGKINS LYMPHOMA
10 0.0000051763 GEMCITABINE//TROXACITABINE//DEOXYCYTIDINE KINASE